<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01221571</url>
  </required_header>
  <id_info>
    <org_study_id>AFM13-101</org_study_id>
    <secondary_id>2010-019232-13</secondary_id>
    <nct_id>NCT01221571</nct_id>
  </id_info>
  <brief_title>A Study to Assess AFM13 in Patients With Hodgkin Lymphoma</brief_title>
  <official_title>A Pharmacodynamically-Guided Dose Escalation Phase I Study to Assess the Safety of AFM13 (Recombinant Antibody Construct Against Human CD30 and CD16A) in Patients With Refractory and/or Relapsed Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affimed GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affimed GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the safety, tolerability, pharmacokinetics and activity&#xD;
      of single cycles of AFM13 in patients with CD30 positive refractory and/or relapsed Hodgkin&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:&#xD;
&#xD;
      The overall objective of this study is to determine the safety, tolerability,&#xD;
      pharmacokinetics and activity of single cycles of AFM13 in patients with CD30 positive&#xD;
      refractory and/or relapsed Hodgkin lymphoma.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. To determine the safety and tolerability of increasing doses of single cycles of AFM13&#xD;
           monotherapy.&#xD;
&#xD;
        2. To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13;&#xD;
           whichever is reached first.&#xD;
&#xD;
        3. To define the pharmacokinetic profile of AFM13.&#xD;
&#xD;
        4. To analyse immunological markers e.g. ADCC (Antibody dependent cell mediated&#xD;
           cytotoxicity), NK (Natural killer) cell activity, complement activation and depletion,&#xD;
           and cytokine release.&#xD;
&#xD;
        5. To assess the immunogenicity of AFM13.&#xD;
&#xD;
        6. To assess the activity of AFM13.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of AFM13 monotherapy.</measure>
    <time_frame>Length of Study</time_frame>
    <description>Measure occurrence of adverse events and monitor laboratory safety parameters. Immunogenicity of AFM13.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the OBD (Optimal Biological Dose) or MTD (Maximum Tolerated Dose) of AFM13</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To define the pharmacokinetic profile of AFM13.</measure>
    <time_frame>Length of study</time_frame>
    <description>To test levels of AFM13 in blood samples and assess curve compared to dose of AFM13 administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyse immunological markers of activity</measure>
    <time_frame>Length of study</time_frame>
    <description>ADCC, NK cell, Complement and Cytokine levels in the serum will be measured at different time points to assess the level of activity resulting from administration of AFM13.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the immunogenicity of AFM13.</measure>
    <time_frame>length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of AFM13</measure>
    <time_frame>length of study</time_frame>
    <description>To measure immunological activity useing biomarkers in the blood and to measure response of the disease in FDG-PET and CT scans.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>AFM13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV (intravenous) infusion, dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFM 13</intervention_name>
    <description>Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.</description>
    <arm_group_label>AFM13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological diagnosis of relapsed or refractory Hodgkin lymphoma expressing the CD30&#xD;
             antigen.&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. Both genders.&#xD;
&#xD;
          4. Patients who have relapsed or are refractory after at least two prior potentially&#xD;
             curative therapies including autologous stem cell transplantation (ASCT). Patients&#xD;
             with a progressive disease after the first-line therapy who are ineligible for, or&#xD;
             refused to receive high dose chemotherapy and/or ASCT for the second-line therapy, or&#xD;
             any other established curative therapy, are also eligible.&#xD;
&#xD;
          5. Completed radiotherapy, chemotherapy, and/or treatment with other investigational&#xD;
             agents at least 3 weeks prior to study entry.&#xD;
&#xD;
          6. Patients who received ASCT should have fully recovered prior to study entry.&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) status of ≤2.&#xD;
&#xD;
          8. Laboratory data:&#xD;
&#xD;
               1. Platelet count &gt;75,000/mm3;&#xD;
&#xD;
               2. Hemoglobin &gt;9.0 g/dL (may be maintained by transfusion);&#xD;
&#xD;
               3. Absolute neutrophil count &gt;1500/mm3;&#xD;
&#xD;
               4. ALT/AST (Alanine aminotransferase/Aspartate aminotransferase)&lt;2.5 times the upper&#xD;
                  limit of normal (ULN);&#xD;
&#xD;
               5. Total bilirubin &lt;1.5 times ULN;&#xD;
&#xD;
               6. Creatinine &lt;1.5 mg/dL.&#xD;
&#xD;
          9. Female patients of childbearing potential who are not surgically sterile or&#xD;
             postmenopausal and male patients who are not surgically sterile must agree to use&#xD;
             medically effective contraception during the treatment period and up to 60 days after&#xD;
             the last AFM13 administration. The patient must agree to sign his or her consent on&#xD;
             this particular inclusion criterion.&#xD;
&#xD;
         10. Ability to give written, informed consent prior to any study-specific screening&#xD;
             procedures, with the understanding that the consent may be withdrawn by the patient at&#xD;
             any time without prejudice.&#xD;
&#xD;
         11. Be willing and able to comply with the study protocol for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant diseases (other than HL (Hodgkin Lymphoma)) or clinically significant&#xD;
             findings, including psychiatric and behavioral problems, medical history and/or&#xD;
             physical examination findings that would preclude the patient from participating in&#xD;
             the study.&#xD;
&#xD;
          2. History or clinical evidence of central nervous system (CNS) HL.&#xD;
&#xD;
          3. Allogeneic SCT.&#xD;
&#xD;
          4. Major surgery within 4 weeks prior to study entry.&#xD;
&#xD;
          5. Known hypersensitivity to recombinant proteins or any excipient contained in the drug&#xD;
             formulation.&#xD;
&#xD;
          6. Known history of another primary malignancy that has not been in remission for at&#xD;
             least 5 years. Non-concurrent non-melanoma skin cancer and cervical carcinoma in situ&#xD;
             or squamous intraepithelial lesions (e.g., cervical intraepithelial neoplasia [CIN] or&#xD;
             prostatic intraepithelial/intraductal neoplasia [PIN]) are allowed.&#xD;
&#xD;
          7. Any active viral, bacterial, or systemic fungal infection within 4 weeks prior to&#xD;
             study entry.&#xD;
&#xD;
          8. Known to be positive for human immunodeficiency virus (HIV), hepatitis B virus surface&#xD;
             antigen (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
          9. History of significant chronic or recurrent infections requiring treatment.&#xD;
&#xD;
         10. Receiving systemic steroid prednisone or equivalent during the 3 weeks immediately&#xD;
             preceding enrollment.&#xD;
&#xD;
         11. Pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Cologne, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anas Younes, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center, Houston, Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Max S Topp, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Würzburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hosptial Cologne</name>
      <address>
        <city>Koln</city>
        <state>Köln</state>
        <zip>50924 Köln</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2010</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>AFM 13</keyword>
  <keyword>Natural killer cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

